You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 115 No. 11, November 1997 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLE
 This Article
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

Ganciclovir implant exchange. Timing, surgical procedure, and complications

D. F. Martin, F. L. Ferris, D. J. Parks, R. C. Walton, S. D. Mellow, D. Gibbs, N. A. Remaley, P. Ashton, M. D. Davis, C. C. Chan and R. B. Nussenblatt
Department of Ophthalmology, Emory University School of Medicine, Atlanta, Ga., USA.

BACKGROUND: The ganciclovir implant is effective for the treatment of cytomegalovirus (CMV) retinitis. The device eventually runs out of drug, however, and must be replaced. We report our experience with exchanging ganciclovir implants during the course of a randomized clinical trial. METHODS: During our study, patients with newly diagnosed peripheral CMV retinitis were treated with a ganciclovir implant. The implant was scheduled for exchange at 32 weeks. It was exchanged earlier if progression of CMV retinitis occurred. Patient examinations and standard fundus photography were performed at 2-week intervals after the exchange procedure. RESULTS: Twenty-six exchange procedures were performed. Twenty-two eyes in 15 patients received a second implant and 4 eyes in 4 patients later received a third implant. Cytomegalovirus retinitis was rendered or maintained inactive in 22 of 23 cases with more than 1 month of follow-up after the second or third implants. Complications after the second implant procedure included transient vitreous hemorrhage in 5 eyes, postoperative inflammation in 1 eye, and retinal detachment in 1 eye. Median visual acuity returned to 20/25 by 28 days and to 20/20 by 42 days. Complications after the third implant procedure included dense vitreous hemorrhage in 3 of 4 eyes. Median survival time after a second implant procedure was 89 days. CONCLUSIONS: The initial ganciclovir implant exchange procedure is well tolerated with continued long-term control of CMV retinitis. Multiple reentries through the same wound may be associated with an increased risk for vitreous hemorrhage.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Intravitreal properties of porous silicon photonic crystals: a potential self-reporting intraocular drug-delivery vehicle
Cheng et al.
Br. J. Ophthalmol. 2008;92:705-711.
ABSTRACT | FULL TEXT  

Treatment or Prevention of Herpes Simplex Virus Retinitis with Intravitreally Injectable Crystalline 1-O-Hexadecylpropanediol-3-Phospho-Ganciclovir
Cheng et al.
IOVS 2002;43:515-521.
ABSTRACT | FULL TEXT  

Scleral Plug of Biodegradable Polymers Containing Ganciclovir for Experimental Cytomegalovirus Retinitis
Sakurai et al.
IOVS 2001;42:2043-2048.
ABSTRACT | FULL TEXT  

Intravitreal Toxicology and Duration of Efficacy of a Novel Antiviral Lipid Prodrug of Ganciclovir in Liposome Formulation
Cheng et al.
IOVS 2000;41:1523-1532.
ABSTRACT | FULL TEXT  

A Single-Suture Technique for Placement of the Ganciclovir Implant
Jones and Weinberg
Arch Ophthalmol 2000;118:584-585.
ABSTRACT | FULL TEXT  

Suture Loop to Aid in Ganciclovir Implant Removal
MacCumber et al.
Arch Ophthalmol 1999;117:1250-1254.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.